Back to top
more

IntraCellular Therapies (ITCI)

(Delayed Data from NSDQ)

$76.69 USD

76.69
2,861,968

-3.15 (-3.95%)

Updated Apr 17, 2024 04:00 PM ET

After-Market: $76.58 -0.11 (-0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals

by Zacks Equity Research

Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.

Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?

by Zacks Equity Research

Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.

Ekta Bagri headshot

Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More

by Ekta Bagri

Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.

Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of 7.88% and 4.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Intra-Cellular Therapies (ITCI) Now Trades Above Golden Cross: Time to Buy?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Intra-Cellular Therapies (ITCI) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Intra-Cellular Therapies (ITCI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Ekta Bagri headshot

3 Biotech Stocks Most Wall Street Analysts Are Bullish About

by Ekta Bagri

Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.

Why Is Biogen Inc. (BIIB) Up 6.4% Since Last Earnings Report?

by Zacks Equity Research

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street Analysts Think Intra-Cellular (ITCI) Could Surge 33.02%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 33% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Intra-Cellular (ITCI) Could Rally 41.19%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised

by Zacks Equity Research

Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth. The company raises its guidance for full-year 2023 Caplyta sales.

Earnings Preview: Cytek Biosciences, Inc. (CTKB) Q3 Earnings Expected to Decline

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised

by Zacks Equity Research

Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth. The company raises its financial outlook for full-year Caplyta sales.

Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 3.97%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Is Reata Pharmaceuticals, Inc. (RETA) Up 6.9% Since Last Earnings Report?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises

by Zacks Equity Research

Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.

Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.